03.10.25 -- Is Your CDMO Using These AI-Driven Solutions In CMC For Oligos And Peptides?

Manufacturing mRNA products is a complex and challenging process that requires careful consideration at each stage. Learn more about the challenges and intricacies involved.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

To ensure the success of gene therapy, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Early product characterization can serve to uncover crucial information about an advanced therapeutic candidate, affording new insight into its CQAs and helping to shape better analytical assays.

Technology transfer, the transmission of bioprocess knowledge, skills and technology, is a crucial mechanism for ensuring adequate and timely access to innovative medicines.

Setting up a CGT product for regulatory viability and commercial success means investing to empower process design, plus on-time planning of PPQ and CPV activities.

Enhancing AAV production efficiency is critical for expanding gene therapy applications — this optimized helper construct significantly boosts yield and potency.

Explore how leveraging a comprehensive biomarker strategy can accelerate clinical trial timelines and improve outcomes for CAR T-cell therapies in oncology and beyond.